Labcorp releases transcript of Q2 2026 earnings call webcast prepared remarks
LH•Q2 results and updated 2026 guidance
Labcorp’s Q2 2026 results webcast drew Chairman and CEO Adam Schechter, CFO Julia Wang, and SVP IR Dewey Steadman.
- Q2 revenue rose 6% to USD 3.7 billion; adjusted operating margin widened 70 bps to 15.8%; adjusted EPS increased 15% to USD 4.99.
- Diagnostics revenue grew 5.5% to USD 2.9 billion; adjusted operating margin improved to 18% from 17.6%.
- Biopharma Laboratory Services revenue climbed 6.5% to USD 836 million; margin expanded to 17% from 15.7%; book-to-bill was 1.14; backlog was USD 8.7 billion.
- Labcorp raised 2026 guidance: revenue growth of 5.4%-6.3%; adjusted EPS of USD 18.10-18.55; free cash flow of USD 1.24-1.36 billion; and a buyback authorization lifted by USD 1 billion to USD 1.4 billion.
